Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $3.02 billion. The enterprise value is $2.82 billion.
| Market Cap | 3.02B |
| Enterprise Value | 2.82B |
Important Dates
The next estimated earnings date is Tuesday, July 30, 2024, before market open.
| Earnings Date | Jul 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 60.97 million shares outstanding. The number of shares has increased by 6.06% in one year.
| Shares Outstanding | 60.97M |
| Shares Change (YoY) | +6.06% |
| Shares Change (QoQ) | +1.55% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 116.48% |
| Float | 45.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.88 |
| Forward PS | 20.01 |
| PB Ratio | 49.08 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 30.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.35, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.35 |
| Quick Ratio | 3.99 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.33 |
Financial Efficiency
Return on equity (ROE) is -179.30% and return on invested capital (ROIC) is -433.64%.
| Return on Equity (ROE) | -179.30% |
| Return on Assets (ROA) | -87.30% |
| Return on Capital (ROIC) | -433.64% |
| Revenue Per Employee | $406,752 |
| Profits Per Employee | -$1.21M |
| Employee Count | 226 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.53 |
Taxes
In the past 12 months, RYTM has paid $864,000 in taxes.
| Income Tax | 864,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +183.10% in the last 52 weeks. The beta is 2.04, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +183.10% |
| 50-Day Moving Average | 41.59 |
| 200-Day Moving Average | 39.02 |
| Relative Strength Index (RSI) | 61.59 |
| Average Volume (20 Days) | 594,664 |
Short Selling Information
The latest short interest is 9.24 million, so 15.15% of the outstanding shares have been sold short.
| Short Interest | 9.24M |
| Short Previous Month | 11.04M |
| Short % of Shares Out | 15.15% |
| Short % of Float | 20.26% |
| Short Ratio (days to cover) | 15.15 |
Income Statement
In the last 12 months, RYTM had revenue of $91.93 million and -$273.87 million in losses. Loss per share was -$4.63.
| Revenue | 91.93M |
| Gross Profit | 81.24M |
| Operating Income | -271.71M |
| Pretax Income | -273.01M |
| Net Income | -273.87M |
| EBITDA | -255.54M |
| EBIT | -257.25M |
| Loss Per Share | -$4.63 |
Balance Sheet
The company has $201.66 million in cash and $1.08 million in debt, giving a net cash position of $200.58 million or $3.29 per share.
| Cash & Cash Equivalents | 201.66M |
| Total Debt | 1.08M |
| Net Cash | 200.58M |
| Net Cash Per Share | $3.29 |
| Equity (Book Value) | 61.58M |
| Book Value Per Share | 1.01 |
| Working Capital | 181.59M |
Cash Flow
| Operating Cash Flow | -140.47M |
| Capital Expenditures | n/a |
| Free Cash Flow | -140.47M |
| FCF Per Share | -$2.34 |
Margins
Gross margin is 88.37%, with operating and profit margins of -295.57% and -297.93%.
| Gross Margin | 88.37% |
| Operating Margin | -295.57% |
| Pretax Margin | -296.99% |
| Profit Margin | -297.93% |
| EBITDA Margin | -277.99% |
| EBIT Margin | -279.84% |
| FCF Margin | -152.80% |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.06% |
| Shareholder Yield | -6.06% |
| Earnings Yield | -9.06% |
| FCF Yield | -4.65% |
Analyst Forecast
The average price target for RYTM is $54.33, which is 9.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $54.33 |
| Price Target Difference | 9.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 68.19% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 1.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.51 |
| Piotroski F-Score | 3 |